MX2022001038A - Métodos para tratar trastornos mediados por anticuerpos con antagonistas de fcrn. - Google Patents
Métodos para tratar trastornos mediados por anticuerpos con antagonistas de fcrn.Info
- Publication number
- MX2022001038A MX2022001038A MX2022001038A MX2022001038A MX2022001038A MX 2022001038 A MX2022001038 A MX 2022001038A MX 2022001038 A MX2022001038 A MX 2022001038A MX 2022001038 A MX2022001038 A MX 2022001038A MX 2022001038 A MX2022001038 A MX 2022001038A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- fcrn antagonist
- antibody
- present disclosure
- provides methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente descripción proporciona métodos para tratar un trastorno mediado por anticuerpos (por ejemplo, una enfermedad autoinmune) utilizando un antagonista de FcRn, por ejemplo, un polipéptido de unión (por ejemplo, un anticuerpo y/o una inmunoadhesina), que comprende un dominio Fc modificado. La presente descripción también proporciona métodos para mejorar la formación de imágenes para diagnóstico utilizando un antagonista de FcRn descrito en la presente memoria. La presente descripción proporciona además métodos para reducir la exposición de un tejido normal a un anticuerpo radiomarcado durante la obtención de imágenes para diagnóstico utilizando un antagonista de FcRn descrito en la presente memoria. También se proporcionan métodos que comprenden administrar a un sujeto una cantidad terapéuticamente eficaz de un antagonista de FcRn descrito en la presente memoria.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962878541P | 2019-07-25 | 2019-07-25 | |
| PCT/US2020/043533 WO2021016571A2 (en) | 2019-07-25 | 2020-07-24 | Methods of treating antibody-mediated disorders with fcrn antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022001038A true MX2022001038A (es) | 2022-04-26 |
Family
ID=72087159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001038A MX2022001038A (es) | 2019-07-25 | 2020-07-24 | Métodos para tratar trastornos mediados por anticuerpos con antagonistas de fcrn. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210024620A1 (es) |
| EP (1) | EP4004039A2 (es) |
| JP (1) | JP2022542884A (es) |
| KR (1) | KR20220038432A (es) |
| CN (1) | CN114466663A (es) |
| AU (1) | AU2020315925A1 (es) |
| BR (1) | BR112022001255A2 (es) |
| CA (1) | CA3148764A1 (es) |
| CO (1) | CO2022001164A2 (es) |
| IL (1) | IL290101A (es) |
| MX (1) | MX2022001038A (es) |
| TW (1) | TW202120539A (es) |
| WO (1) | WO2021016571A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240132624A1 (en) | 2022-07-27 | 2024-04-25 | Ablynx N.V. | Polypeptides binding to a specific epitope of the neonatal fc receptor |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
| AU6873396A (en) | 1995-10-16 | 1997-05-07 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| EP1294904A1 (en) | 2000-06-30 | 2003-03-26 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Heterodimeric fusion proteins |
| CA2536408A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006130834A2 (en) * | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| TWI588156B (zh) | 2011-03-28 | 2017-06-21 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| TW201817744A (zh) * | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| MY172430A (en) * | 2013-04-29 | 2019-11-25 | Hoffmann La Roche | Human fcrn-binding modified antibodies and methods of use |
| EP3155013B1 (en) * | 2014-06-12 | 2019-03-27 | F. Hoffmann-La Roche AG | Method for selecting antibodies with modified fcrn interaction |
| CN107108720A (zh) * | 2014-11-06 | 2017-08-29 | 豪夫迈·罗氏有限公司 | 具有改变的FCRN结合的Fc区变体及其使用方法 |
| PL3268391T3 (pl) * | 2015-03-09 | 2022-01-03 | Argenx Bvba | Sposoby zmniejszania poziomów środków zawierających Fc w surowicy z zastosowaniem antagonistów FcRn |
| GB201618424D0 (en) * | 2016-11-01 | 2016-12-14 | Argenix Bvba | Treatment of antibody mediated disease |
| EP3625251A1 (en) * | 2017-05-15 | 2020-03-25 | University Of Rochester | Broadly neutralizing anti-influenza monoclonal antibody and uses thereof |
| BR112020011483A2 (pt) * | 2017-12-08 | 2020-11-24 | Argenx Bvba | uso de antagonistas de fcrn para tratamento de miastenia gravis generalizada |
| CN111788221A (zh) * | 2018-01-26 | 2020-10-16 | 建新公司 | 具有与FcRn增强的结合及延长的半衰期的Fc变体 |
-
2020
- 2020-07-24 MX MX2022001038A patent/MX2022001038A/es unknown
- 2020-07-24 EP EP20757029.2A patent/EP4004039A2/en active Pending
- 2020-07-24 BR BR112022001255A patent/BR112022001255A2/pt unknown
- 2020-07-24 US US16/938,727 patent/US20210024620A1/en active Pending
- 2020-07-24 CA CA3148764A patent/CA3148764A1/en active Pending
- 2020-07-24 JP JP2022504569A patent/JP2022542884A/ja active Pending
- 2020-07-24 KR KR1020227005875A patent/KR20220038432A/ko unknown
- 2020-07-24 CN CN202080067562.1A patent/CN114466663A/zh active Pending
- 2020-07-24 AU AU2020315925A patent/AU2020315925A1/en active Pending
- 2020-07-24 WO PCT/US2020/043533 patent/WO2021016571A2/en active Application Filing
- 2020-07-24 TW TW109125184A patent/TW202120539A/zh unknown
-
2022
- 2022-01-24 IL IL290101A patent/IL290101A/en unknown
- 2022-02-04 CO CONC2022/0001164A patent/CO2022001164A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022001255A2 (pt) | 2022-06-14 |
| EP4004039A2 (en) | 2022-06-01 |
| KR20220038432A (ko) | 2022-03-28 |
| IL290101A (en) | 2022-03-01 |
| CO2022001164A2 (es) | 2022-03-08 |
| WO2021016571A3 (en) | 2021-03-04 |
| TW202120539A (zh) | 2021-06-01 |
| AU2020315925A1 (en) | 2022-03-03 |
| US20210024620A1 (en) | 2021-01-28 |
| WO2021016571A2 (en) | 2021-01-28 |
| CN114466663A (zh) | 2022-05-10 |
| CA3148764A1 (en) | 2021-01-28 |
| JP2022542884A (ja) | 2022-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009009379A (es) | Metodos y composiciones para tratar enfermedades tumorales. | |
| RU2015104760A (ru) | Связывающие kir3dl2 агенты | |
| NZ590131A (en) | Notch-binding agents and antagonists and methods of use thereof | |
| MX2020012567A (es) | Anticuerpos anti-ox40 y metodos de uso. | |
| AU2024202552A1 (en) | Neutralization of inhibitory pathways in lymphocytes | |
| JP2018044014A (ja) | 脱髄障害の治療のための併用療法および使用 | |
| WO2007145840A3 (en) | Compositions and methods for diagnosing and treating cancer | |
| ZA202101325B (en) | Anti-ifnar1 antibodies for treating autoimmune disease | |
| RU2019114679A (ru) | Средства, пути применения и способы лечения синуклеопатии | |
| JP2007522096A5 (es) | ||
| BRPI0621800B8 (pt) | anticorpos que se ligam à proteína fzd10, clones de hibridoma, composições farmacêuticas, kit compreendendo os referidos anticorpos, e método para diagnose ou prognose de uma doença que é associada a homólogo fzd10 ou de uma predisposição para desenvolver a doença em um indivíduo | |
| MXPA06012601A (es) | Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos. | |
| MX2007006921A (es) | Composiciones que comprenden anticuerpos del receptor anti-factor de crecimiento tipo insulina 1 y metodos para obtener los anticuerpos. | |
| CL2021003327A1 (es) | Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089). | |
| MX2021008958A (es) | Proteínas de unión a antígeno del receptor gamma anti-il2. | |
| MX2021011715A (es) | Anticuerpos contra amiloide-? con piroglutamato y usos de estos campo de la invención. | |
| NZ569428A (en) | Treatment of conditions involving demyelination with a Sp35 antagonist | |
| MA37761A1 (fr) | Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations | |
| MX2020012081A (es) | Anticuerpos totalmente humanos contra ox40, metodo para preparar los mismos y su uso. | |
| JP2017512838A5 (es) | ||
| EA202092162A1 (ru) | Антитела против cxcl13 для лечения аутоиммунных заболеваний и рака | |
| MX2022001038A (es) | Métodos para tratar trastornos mediados por anticuerpos con antagonistas de fcrn. | |
| MX2022003466A (es) | Interrupción de los tejidos tumorales al dirigir la proteína de activación de fibroblastos (fap). | |
| Sanchorawala et al. | Safety and tolerability of daratumumab in patients with relapsed light chain (AL) amyloidosis: preliminary results of a phase II study | |
| EA202100199A1 (ru) | Моноклональные антитела, специфически связывающиеся с trbv-9 человека |